THTX - Theratechnologies

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Theratechnologies reports Q4 earnings miss; initiates FY23 outlook
• Theratechnologies slumps 30% as cancer drug trial enrollment paused on efficacy, safety woes
• Theratechnologies reports Q3 results, FY22 guidance on track
• Theratechnologies stock rises 9% on positive data from early-stage trial data of cancer therapy
• Theratechnologies revenue of $19.27M misses by $0.86M, tightens FY2022 revenue outlook
• Theratechnologies stock gains on securing $100M term loan
• Theratechnologies begin enrollment in early-stage study of TH1902 in advanced cancers
• Theratechnologies reports Q1 results
• Theratechnologies GAAP EPS of -$0.34 misses by $0.26, revenue of $18.75M misses by $1.73M
• Theratechnologies net loss widens in Q3
• Theratechnologies EPS misses by $0.03, misses on revenue
• Theratechnologies reports positive results for Trogarzo IV push administration study
• Theratechnologies EPS in-line, misses on revenue
• Theratechnologies adds Frank Holler to board
• Theratechnologies reports Trogarzo results at ACTHIV 2021 meeting
• Theratechnologies EPS misses by $0.03, misses on revenue
• Dosing underway in Theratechnologies early-stage study of TH1902 in SORT1+ solid tumors
• Theratechnologies EPS in-line, beats on revenue
• Theratechnologies surges after fast track designation from FDA
• Theratechnologies launches $40M bought-deal offering